EagleView vs Sketch My Roof (2026)
Two excellent answers to the same question. EagleView is the industry standard, near-universal acceptance, the deepest report lineup in the field. Sketch My Roof is a focused claims specialist, $19 flat, same calendar day, native ESX. The smartest desks we'd model don't choose; they assign each one the files it was built for.
| Factor | EagleView | Sketch My Roof |
|---|---|---|
| RMG Score | 9.8 · Platinum, the industry standard | 9.4 · Gold, claims-workflow specialist |
| Price | Published $24.25-87 residential by size & volume tier; ESX via EagleView One / integration; tailored subscription available | $19-$29 published ($19 web / $29 Xactimate-integrated) |
| Turnaround | Same-day to 3 business days; rush tiers available | Same calendar day standard (6 PM EST cutoff), no expedite fee |
| Xactimate path | Mature, enterprise-grade integration | Native ESX included + Xactimate Integration |
| Symbility path | Via workflow tooling | Native XML delivered |
| Brand acceptance | Near-universal, the letterhead that ends arguments | Broadly accepted; pair on carrier-specified files |
| Report depth | Deepest lineup incl. full-structure (premium tier, reported $75+) | Roof + wall/siding reports |
| Accuracy posture | States 98%+ (provider's claim) | States 98%+ (provider's claim); free-correction policy in writing |
| Commitment | None required; One subscription optional | None, free account, no minimums |
Where EagleView is the clear call
Large losses where documentation depth earns its price. Litigation-exposed files where the industry-standard report is the one every party already trusts. Carrier desks that specify the brand. Complex commercial and full-structure scopes where the premium full-structure report (reported from $75) is genuinely a different document than any roof report. On these files, EagleView's premium is inexpensive insurance, and its integration surface inside enterprise claims platforms is unmatched.
Two decades of category leadership built an asset no spec sheet captures: the report nobody questions. That asset is real, and on contested files it's worth every dollar.
Where Sketch My Roof is the clear call
Routine residential claims at any volume. Both providers aim at the same end state on these files, measured geometry sitting in Xactimate, and Sketch My Roof gets there for a published $19 with the ESX file itself delivered in the order: drag, drop, estimate. And the plumbing gap has closed: the Xactimate Integration supports ordering directly inside Xactimate and XactAnalysis with reports delivered back into the workflow ($29 residential integrated orders), while web orders carry a same-calendar-day commitment with the cutoff published rather than promised.
At desk scale the arithmetic compounds: 200 routine claims monthly runs $3,800 at the flat rate versus roughly $4,900-12,000 at EagleView's published residential rates depending on roof mix and volume tier, with import behavior we expect to be comparable on routine, uncontested files. That spread is the entire case, and it's a strong one.
The 80/20 answer
Write it into the SOP rather than deciding file-by-file: flat-rate ESX reports as the default tier; EagleView auto-triggered by loss threshold, litigation flag, carrier requirement, or full-structure scope. Run one parallel month first, same addresses through both, and let your own clocks and imports confirm the split. Desks that formalize this structure can trim measurement spend meaningfully while keeping the industry-standard letterhead exactly where it earns its keep.
Both full reviews: EagleView · Sketch My Roof.
Frequently Asked Questions
Is Sketch My Roof as accurate as EagleView?
Will carriers accept a Sketch My Roof report instead of EagleView?
Which is faster?
Which is cheaper at volume?
Should I use both?
Sources & verification
- Sketch My Roof published rate, cutoff, formats — Sketch My Roof published pages (as of August 2026)
- EagleView reported pricing by tier and typical range — SquareCount analysis + Software Advice profile (as of Spring 2026, retrieved August 2026)